Q4 2022 EPS Estimates for ViewRay, Inc. Cut by Oppenheimer (NASDAQ:VRAY)

ViewRay, Inc. (NASDAQ:VRAYGet Rating) – Oppenheimer reduced their Q4 2022 earnings estimates for shares of ViewRay in a research note issued on Wednesday, August 3rd. Oppenheimer analyst S. Kalia now anticipates that the company will earn ($0.14) per share for the quarter, down from their prior forecast of ($0.13). The consensus estimate for ViewRay’s current full-year earnings is ($0.56) per share.

ViewRay (NASDAQ:VRAYGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. ViewRay had a negative net margin of 131.20% and a negative return on equity of 72.91%. The company had revenue of $18.88 million during the quarter, compared to the consensus estimate of $15.62 million. During the same quarter in the prior year, the company posted ($0.17) EPS. The company’s quarterly revenue was up 21.6% compared to the same quarter last year.

A number of other research firms also recently commented on VRAY. BTIG Research dropped their price objective on shares of ViewRay from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Piper Sandler dropped their target price on shares of ViewRay from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.00.

ViewRay Trading Up 3.3 %

NASDAQ VRAY opened at $3.41 on Friday. ViewRay has a 12 month low of $2.39 and a 12 month high of $8.25. The company has a 50-day moving average of $2.89 and a 200-day moving average of $3.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.17 and a quick ratio of 2.84. The company has a market cap of $615.36 million, a P/E ratio of -5.68 and a beta of 1.15.

Institutional Trading of ViewRay

Several large investors have recently bought and sold shares of the company. Royce & Associates LP grew its position in ViewRay by 100.0% in the second quarter. Royce & Associates LP now owns 200,000 shares of the company’s stock valued at $530,000 after acquiring an additional 100,000 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of ViewRay by 6.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 176,769 shares of the company’s stock valued at $468,000 after buying an additional 10,138 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of ViewRay by 104.7% during the 2nd quarter. SG Americas Securities LLC now owns 40,550 shares of the company’s stock valued at $107,000 after buying an additional 20,745 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in shares of ViewRay by 31.0% during the 2nd quarter. Perkins Capital Management Inc. now owns 43,500 shares of the company’s stock valued at $115,000 after buying an additional 10,300 shares during the last quarter. Finally, Hodges Capital Management Inc. purchased a new position in shares of ViewRay during the 2nd quarter valued at approximately $265,000. Institutional investors and hedge funds own 86.04% of the company’s stock.

Insider Buying and Selling

In other ViewRay news, Director Brian K. Roberts bought 16,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 18th. The stock was purchased at an average price of $2.98 per share, with a total value of $47,680.00. Following the transaction, the director now owns 147,761 shares in the company, valued at $440,327.78. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Caley Castelein acquired 1,065,000 shares of the stock in a transaction on Wednesday, May 11th. The stock was bought at an average price of $2.54 per share, with a total value of $2,705,100.00. Following the completion of the transaction, the director now directly owns 1,545,600 shares of the company’s stock, valued at $3,925,824. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian K. Roberts acquired 16,000 shares of the stock in a transaction on Wednesday, May 18th. The stock was purchased at an average cost of $2.98 per share, with a total value of $47,680.00. Following the transaction, the director now directly owns 147,761 shares of the company’s stock, valued at $440,327.78. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 1,231,000 shares of company stock valued at $3,149,280. 4.80% of the stock is currently owned by corporate insiders.

About ViewRay

(Get Rating)

ViewRay, Inc designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns.

Read More

Earnings History and Estimates for ViewRay (NASDAQ:VRAY)

Receive News & Ratings for ViewRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay and related companies with MarketBeat.com's FREE daily email newsletter.